Reportstack has announced a new pharma report on Microvascular Complications of Diabetes – Global Drug Forecast and Market Analysis to 2022. The report states that out of the 7MM, the US will show the highest growth in the MCD treatment market, with its total value jumping from $1.8 billion in 2012 to $3.7 billion by 2022, at a CAGR of 7.3%. The US will be followed by the five European countries, with their combined market values expected to increase from $777 million in 2012 to $1.3 billion by 2022, at a CAGR of 5.4%.
Valentina Gburcik, Ph.D., GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, says: “America’s rapid MCD market growth is due to the rising overall prevalence of type 2 diabetes in the country, thanks to its skyrocketing obesity epidemic, which is resulting in the subsequent increase in diabetic complications.” GlobalData anticipates that the launch of AbbVie’s atrasentan in 2018 will further boost global diabetic nephropathy treatment sales, which are expected to reach $1.8 billion by 2022. Additionally, the diabetic retinopathy and neuropathy therapeutics market values are also expected to increase by the end of the forecast period, reaching $2.7 billion and $1.8 billion, respectively.
Gburcik continues: “The approval of Lucentis and Eylea for diabetic macular edema in 2012 and 2014, respectively, will overtake the patient share from the much cheaper off-label Avastin, which will drive the diabetic retinopathy market during the forecast period. “On the other hand, the only driver behind the diabetic neuropathy market, besides the prevalence of the disease, will be a slow increase in opioid consumption by 2017, as the arena is being overtaken by generic drugs.”
Despite the success of the MCD pharmaceutical market, Gburcik says that the current therapies still leave a very high number of unmet needs. These include the requirement for a unified treatment aimed at the underlying cause of all microvascular complications, an optimization of personalized therapy, and a treatment that is able to alter or stop the progressive natural course of diabetic complications. The companies mentioned in this report are Roche, Novartis, Regeneron, Bayer, Eli Lilly, Pfizer and AbbVie.
Key Findings in this report are
- The main driver of the enormous expansion of the MCD market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and scyrocketting increase in diabetes prevalence.
- The major global barrier for all microvascular complications is the sparsely populated pipeline, while the diabetic neuropathy and nephropathy segments also face the barrier in an increasing number of generic competitors.
- The whole anti-VEGF class, used for the treatment of diabetic macular edema, will experience steady growth, while the market entry of AbbVie’s atrasentan, the first novel, branded diabetic nephropathy drug to enter the market in more than 10 years, will noticeably enhance the overall market size.
- High rate of failure in clinical trials for diabetic nephropathy and diabetic neuropathy discouraged many drug developers; however, they are now shifting their strategy towards better understanding of the disease and better design of clinical trials.
- None of the current therapies for the diabetic complications are able to alter their progressive natural course. This unmet need presents a large opportunity for investment by drug developers.
Please visit microvascular complications of diabetes (MCD) pharmaceutical market report to know more details about this report.